These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 30093503)

  • 1. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
    Drilon A; Ou SI; Cho BC; Kim DW; Lee J; Lin JJ; Zhu VW; Ahn MJ; Camidge DR; Nguyen J; Zhai D; Deng W; Huang Z; Rogers E; Liu J; Whitten J; Lim JK; Stopatschinskaja S; Hyman DM; Doebele RC; Cui JJ; Shaw AT
    Cancer Discov; 2018 Oct; 8(10):1227-1236. PubMed ID: 30093503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer.
    Desilets A; Repetto M; Drilon A
    Clin Transl Med; 2024 Oct; 14(10):e70017. PubMed ID: 39402859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
    Yun MR; Kim DH; Kim SY; Joo HS; Lee YW; Choi HM; Park CW; Heo SG; Kang HN; Lee SS; Schoenfeld AJ; Drilon A; Kang SG; Shim HS; Hong MH; Cui JJ; Kim HR; Cho BC
    Clin Cancer Res; 2020 Jul; 26(13):3287-3295. PubMed ID: 32269053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry.
    Li W; Perpinioti N; Schinkel AH; Beijnen JH; Sparidans RW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 May; 1144():122098. PubMed ID: 32278292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
    Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
    Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repotrectinib: First Approval.
    Dhillon S
    Drugs; 2024 Feb; 84(2):239-246. PubMed ID: 38279972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
    Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
    Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repotrectinib in
    Drilon A; Camidge DR; Lin JJ; Kim SW; Solomon BJ; Dziadziuszko R; Besse B; Goto K; de Langen AJ; Wolf J; Lee KH; Popat S; Springfeld C; Nagasaka M; Felip E; Yang N; Velcheti V; Lu S; Kao S; Dooms C; Krebs MG; Yao W; Beg MS; Hu X; Moro-Sibilot D; Cheema P; Stopatschinskaja S; Mehta M; Trone D; Graber A; Sims G; Yuan Y; Cho BC;
    N Engl J Med; 2024 Jan; 390(2):118-131. PubMed ID: 38197815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]).
    Ou SI; Hagopian GG; Zhang SS; Nagasaka M
    J Thorac Oncol; 2024 May; 19(5):706-718. PubMed ID: 38070596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.
    Murray BW; Rogers E; Zhai D; Deng W; Chen X; Sprengeler PA; Zhang X; Graber A; Reich SH; Stopatschinskaja S; Solomon B; Besse B; Drilon A
    Mol Cancer Ther; 2021 Dec; 20(12):2446-2456. PubMed ID: 34625502
    [No Abstract]   [Full Text] [Related]  

  • 12. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
    Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting TRK: A fast-tracked application of precision oncology and future directions.
    Kojadinovic A; Laderian B; Mundi PS
    Crit Rev Oncol Hematol; 2021 Sep; 165():103451. PubMed ID: 34389458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
    Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
    Keddy C; Shinde P; Jones K; Kaech S; Somwar R; Shinde U; Davare MA
    Mol Cancer Ther; 2022 Feb; 21(2):336-346. PubMed ID: 34907086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
    Katayama R; Gong B; Togashi N; Miyamoto M; Kiga M; Iwasaki S; Kamai Y; Tominaga Y; Takeda Y; Kagoshima Y; Shimizu Y; Seto Y; Oh-Hara T; Koike S; Nakao N; Hanzawa H; Watanabe K; Yoda S; Yanagitani N; Hata AN; Shaw AT; Nishio M; Fujita N; Isoyama T
    Nat Commun; 2019 Aug; 10(1):3604. PubMed ID: 31399568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
    Drilon A; Nagasubramanian R; Blake JF; Ku N; Tuch BB; Ebata K; Smith S; Lauriault V; Kolakowski GR; Brandhuber BJ; Larsen PD; Bouhana KS; Winski SL; Hamor R; Wu WI; Parker A; Morales TH; Sullivan FX; DeWolf WE; Wollenberg LA; Gordon PR; Douglas-Lindsay DN; Scaltriti M; Benayed R; Raj S; Hanusch B; Schram AM; Jonsson P; Berger MF; Hechtman JF; Taylor BS; Andrews S; Rothenberg SM; Hyman DM
    Cancer Discov; 2017 Sep; 7(9):963-972. PubMed ID: 28578312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers.
    Thawani R; Repetto M; Keddy C; Nicholson K; Jones K; Nusser K; Beach CZ; Harada G; Drilon A; Davare MA
    bioRxiv; 2024 Jan; ():. PubMed ID: 38293020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
    Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
    J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.
    Drilon A; Horan JC; Tangpeerachaikul A; Besse B; Ou SI; Gadgeel SM; Camidge DR; van der Wekken AJ; Nguyen-Phuong L; Acker A; Keddy C; Nicholson KS; Yoda S; Mente S; Sun Y; Soglia JR; Kohl NE; Porter JR; Shair MD; Zhu V; Davare MA; Hata AN; Pelish HE; Lin JJ
    Cancer Discov; 2023 Mar; 13(3):598-615. PubMed ID: 36511802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.